15 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 15 of 15 clinical reviews.
A comprehensive clinical review of eszopiclone (Lunesta) safety signals, FDA regulatory actions, boxed warnings, dose reductions, and post-market surveillance findings with cited evidence.
Eszopiclone (Lunesta) can impair driving up to 11 hours after a 3 mg dose and cause withdrawal after just 2 weeks nightly use. See risks and contraindications.
A framework for tapering off Lunesta (eszopiclone) after regular use, covering rebound insomnia, taper pacing, CBT-I bridging, and when to involve a prescriber. Pending qualified medical review.
A guide to eszopiclone food and supplement interactions, including alcohol, grapefruit, fatty meals, valerian, melatonin, CBD, and more.
Evidence-based guide to eszopiclone (Lunesta) dosing in older adults. Covers FDA-recommended starting doses, pharmacokinetic changes after 65, falls risk, CYP3A4 interactions, and deprescribing strategies.
A clinician-level review of eszopiclone's long-term cardiovascular effects, covering autonomic modulation, blood pressure data, arrhythmia risk, and what prescribers should monitor in patients taking Lunesta chronically.
A citation-dense guide to every clinically significant drug-drug interaction with eszopiclone (Lunesta): CYP3A4 inhibitors, CNS depressants, opioids, antifungals, and more, with specific pharmacokinetic data and management recommendations.
A clinician-level breakdown of eszopiclone (Lunesta) cost, mechanism, and head-to-head comparison with zolpidem, zaleplon, benzodiazepines, doxepin, ramelteon, suvorexant, and lemborexant. Evidence-cited. Dosing tables included.
A clinician-level review of eszopiclone (Lunesta) and its reported effects on hair and skin, including dermatologic adverse events from FDA labeling, published trials, and real-world pharmacovigilance data.
Evidence-based guidance on what to do when you miss a dose of Lunesta (eszopiclone), including timing thresholds, rebound insomnia risks, and when to resume your normal schedule.
A clinician-grade review of eszopiclone (Lunesta) pharmacokinetics covering absorption, distribution, metabolism via CYP3A4/CYP2E1, and renal elimination, with dose-adjustment guidance for special populations.
When should you stop Lunesta (eszopiclone) before surgery? Learn the evidence-based hold window, drug interactions, CNS depression risks, and what to tell your anesthesia team.
Eszopiclone (Lunesta) is FDA-approved in the US but unavailable in Europe, Canada, and the UK, where the racemic parent compound zopiclone fills the same therapeutic niche. This article explains why.
A clinical review of how eszopiclone (Lunesta) may affect libido, arousal, and hormonal signaling, what is established versus unproven, and a practical framework for sorting sedation from true sexual suppression.
Evidence-based protocols for switching between eszopiclone (Lunesta) and other sedative-hypnotics, including zaleplon, zolpidem, suvorexant, and lemborexant, with clinical timelines and dose equivalencies.